KRAS and neoplasm: The ORR was higher in patients with KRAS exon 2 wild-type tumours (87.5%, 95% CI 61.7–98.4) compared with those with KRAS exon 2 mutated tumours (55.6%, 95% CI 21.2–86.3), with all four complete responses reported in the study occurring in patients with KRAS exon 2 wild-type tumours.